Evaluation of dose-intense ifosfamide, with and without edatrexate, in adults with sarcoma Journal Article


Authors: Casper, E. S.; Schwartz, G. M.; Leung, D.; Sugarman, A.; Bertino, J. R.
Article Title: Evaluation of dose-intense ifosfamide, with and without edatrexate, in adults with sarcoma
Abstract: Purpose. To define the maximally tolerated dose (MTD) of ifosfamide when given with G-CSF on an every other week schedule, and to define the MTD of edatrexate that can be given every two weeks with an intense schedule of ifosfamide. Patients and Methods. Forty-one patients with metastatic or unresectable, locally advanced sarcoma participated in this 2-step phase I trial. The starting dose of ifosfamide was 10 mg/m2 given by continuous intravenous infusion over 4 days every 2 weeks. When the MTD was defined, edatrexate, beginning at a dose of 40 mg/m2 intravenously every 2 weeks was added in subsequent cohorts of patients. Results. Myelosuppression was the most prominent toxicity. Fatigue, nausea, and vomiting were observed in the majority of patients. Ifosfamide 12 gm/m2 given every 2 weeks approached or exceeded the MTD. Edatrexate 100 mg/m2 could be given safety as an intravenous bolus with ifosfamide 10 gm/m2 every 2 weeks. Therapeutic responses were observed in patients with measurable disease. Conclusions. This study demonstrates the feasibility of administering a dose-intense schedule of ifosfamide alone or ifosfamide with edatrexate that might be applied in the adjuvant or neo-adjuvant setting.
Keywords: adult; clinical article; treatment outcome; aged; clinical trial; drug tolerability; fatigue; dose response; drug safety; treatment planning; bone marrow suppression; blood toxicity; nausea; vomiting; cancer therapy; ifosfamide; sarcoma; recombinant granulocyte colony stimulating factor; intravenous drug administration; edatrexate; subcutaneous drug administration; human; male; female; priority journal; article
Journal Title: Sarcoma
Volume: 3
Issue: 2
ISSN: 1357-714X
Publisher: Hindawi Publishing Corporation  
Date Published: 1999-01-01
Start Page: 121
End Page: 127
Language: English
DOI: 10.1080/13577149977758
PROVIDER: scopus
PMCID: PMC2395414
PUBMED: 18521274
DOI/URL:
Notes: Article -- Export Date: 16 August 2016 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Denis Heng Yan Leung
    114 Leung
  2. Joseph Bertino
    363 Bertino
  3. Ephraim S Casper
    108 Casper